Printer Friendly
The Free Library
4,488,576 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Gamma Pharmaceuticals Inc. Achieves Important Sales Milestone.


LAS VEGAS -- Gamma Pharmaceuticals Inc. (OTCBB:GMPM) announced that the Company had completed shipping of the first 100,000 units of a product manufactured using Gamma's innovative Gel Delivery Technology([R]) to a national retail customer.

Peter Cunningham, Gamma's Chief Executive Officer, highlighted that "Gamma's innovative Gel Delivery Technology([R]) and unique product formulation capabilities enable Gamma to produce one of the most distinctive supplement products in the market today. Gamma's Gum Drop product form has been very well received by the consumer as demonstrated by achieving this important milestone. This milestone substantiates our own consumer research findings that there is strong consumer preference for products manufactured using Gamma's Gel Delivery Technology([R])." He went on to say, "The pace of shipment for this new product has been rapid, though in line with our expectations for each of Gamma's Gel product commercialization efforts."

Gamma Pharmaceuticals Inc. is a marketing and product formulation company focused on developing, marketing, and selling innovative product lines of nutritional supplements, personal care products and OTC pharmaceutical products in Greater China (China, Hong Kong & Taiwan) and the United States. Gamma's product formulations, based on its proprietary "Gel Delivery Technology" (Gel Delivery Technology Gamma([R])) are marketed and sold in categories growing at 60% per year and generally described as "wellness products." Gamma offers consumers one of the industry's only full suite of gel product forms, including solid gels, liquid gels, crystal gels and gel strips. Gamma's leading position in gel technologies enables the Company to profit from consumer preferences which are moving away from pills and capsules and towards new and more effective gel product forms. Gamma presents consumers with a choice that offers a more pleasant experience with convenient, great tasting and fast acting product forms.

Gamma master brands include: Brilliant Choice[TM], Savvy Choice[TM] and AirDefense[TM] Vitamins , Nutritional Supplements and Immune Boosters; iceDROP Instant Hand Sanitizer[TM] (Beijing); Diabetes Type II / Pre-Diabetes, Stress reduction, Cognition, Well being, Menopause Symptoms, and Personal Care Products. Youth targeted products are sold as Jugular[TM] Energy - "Go for the Jugular[TM]." Gamma also develops and manufactures house brands for major retailers. At this time Gamma is holding licenses for 9 SKUs in China.

Gamma targets consumers in the fast growing Greater China and U.S. wellness and healthcare markets (LOHAS) and the youth energy products market with our Gel products. Primary Channels are retail pharmacies, supermarkets, club stores and other big box outlets, as well as the U.S. Military. Secondary channels are Internet and direct selling. Gamma uses third party distributors or sells direct to retail.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 24, 2008
Words:515
Previous Article:Avnet, Inc. Reports Third Quarter Fiscal Year 2008 Results.(Financial report)
Next Article:Lux Biosciences Reports on Pivotal Programs in Uveitis and Corneal Transplant Rejection at ARVO Meeting.
Topics:

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles